Peter R. Galle

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial

Thomas Yau, Peter R. Galle, Thomas Decaens et al. · The Lancet · 2025 · 270 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab

Linda Y. Wu, Claudia Angela Maria Fulgenzi, Antonio D’Alessio et al. · Cancers · 2022 · 70 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Treating hepatitis D with bulevirtide – Real-world experience from 114 patients

Christopher Dietz-Fricke, Frank Tacke, Caroline Zöllner et al. · JHEP Reports · 2023 · 61 citations · Full text

Pharmacy, Internal Medicine, Pharmacotherapy +12

A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma

Lorenz Balcar, Bernhard Scheiner, Claudia Angela Maria Fulgenzi et al. · JHEP Reports · 2023 · 26 citations · Full text

Life Sciences, Immunology, Oncology +17

Elevated serum levels of glial fibrillary acidic protein are associated with covert hepatic encephalopathy in patients with cirrhosis

Simon Johannes Gairing, Sven Danneberg, Leonard Kaps et al. · JHEP Reports · 2023 · 20 citations · Full text

Medicine, Biochemistry, Pathology +11